TY - JOUR T1 - Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/1393003.congress-2017.PA3821 VL - 50 IS - suppl 61 SP - PA3821 AU - Veronika Müller AU - Nesrin Mogulkoc AU - Martina Šterclová AU - Beata Zolnowska AU - Vladimír Bartoš AU - Martina Plačková AU - Ladislav Lacina AU - Robert Slivka AU - Martina Doubková AU - Marina Roksandić Milenkovic AU - Radka Bittenglová AU - Imrich Jonner AU - Magdalena Martusewicz-Boros AU - Monika Žurková AU - Ilona Binková AU - Małgorzata Sobiecka AU - Richard Tyl AU - Marzena Trzaska-Sobczak Marzena Trzaska-Sobczak AU - Pawel Sliwinski AU - Vladimíra Lošťáková AU - Sebastian Majewski AU - Pavlína Lisá AU - Katarzyna Lewandowska AU - Hana Šuldová AU - Jasna Tekavec-Trkanje AU - Amelia Szymanowska-Narloch AU - Lenka Šišková AU - Anikó Bohács AU - Ján Plutinský AU - Bohumil Matula AU - Štefan Tóth AU - František Petřík AU - Bučeková Bučeková AU - Jana Pšíkalová AU - Miklós Zsiray AU - Jaroslav Lněnička AU - Vladimír Řihák AU - Zsuzsanna Szalai AU - Zoltan Baliko AU - Štefan Laššán AU - Pavlína Musilová AU - Imre Lajko AU - Tomáš Snížek AU - Jan Anton AU - Jiří Homolka AU - Peter Palúch AU - Róbert Vyšehradský AU - Renata Králová AU - Jan Kervitzer AU - Maria Szilasi AU - Jan Kus AU - Dragana Jovanovic AU - Marta Hájková AU - Michal Svoboda AU - Jana Strenková AU - Martina Vašáková AU - Daniel Doležal Y1 - 2017/09/01 UR - http://erj.ersjournals.com/content/50/suppl_61/PA3821.abstract N2 - Key feature of IPF is decline in forced vital capacity (FVC) and CO diffusion (DLco), but data on clinical determinants of this change in patients who have established disease are scarce. For a given patient it is unknown if different natural histories represent distinct phenotypes of IPF or if geographic, ethnic or other factors might have influence on progression.The EMPIRE (European Multipartner IPF Registry) is a multicountry IPF register in the CEE region. Out of 1229 patients from the registry 324 with available data on FVC and DLco at inclusion and at 6 months rapid decliners (RD: FVC >10% or DLco >10% in 6 months) and controls (C) were included into the analysis. Clinical characteristics at inclusion were analyzed between groups to find clinical determinants of RD.Average age was 67,4±9.7 years, more males were affected than females (male:female 221:103) most patients had classic signs of UIP on HRCT. Most common comorbidity was hypertension (50.9%), coronary heart disease (20.5%), diabetes (20.1%) and hyperlipidaemia (20.1%). RD of FVC was present in 33.7%, while RD of DLco in 53.3% of patients. Comparison of RD and C patients for smoking status, dyspnoe severity, comorbidities, HRCT pattern, lung function parameters at inclusion, 6 minute walk distance or the presence of pulmonary hypertension did not show any difference between groups.The rate of change in FVC or DLco among IPF patients is highly variable, with 34-53 % of patients showing increased rates of decline in FVC and/or DLco. No clinical characteristics could be identified which can predict rapid decline using the data of EMPIRE registry. ER -